Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile.

Immunotherapy and targeted therapy have been associated with highly significant improvements in survival [ 4–7 ].

also in 132,142 other papers

Non-Caucasian stage III melanoma patients had a small and not quite statistically significant decrease in survival when race was considered in univariate analysis, but this difference dropped out in multivariable analysis considering factors such as payer type, which can influence access to care; there was no difference in outcome between Caucasians and non-Caucasians who received adjuvant immunotherapy.

also in 341 other papers